Results 201 to 210 of about 467,873 (247)

Enhancing Pharmacology Education Through Collaborative Innovation: The Evolution and Future of PRORENATA at an Engineering-Based Medical Program. [PDF]

Pharmacol Res Perspect
Lim MA, Coleman D, Nigh N, Brown C, Saw JJ, Kwan N, Smith L.   +6 more
europepmc   +1 more source

Developmental Programming of Drug Response: Microbiota as a Missing Dimension in Perinatal Drug Discovery. [PDF]

Int J Mol Sci
Zhang Y, Ma L, Wang Y.
europepmc   +1 more source

Eosinophilic Depletion with Benralizumab, Mepolizumab, and Depemokimab: A Modeling Study. [PDF]

J Asthma Allergy
Lukka PB, Penland RC, Brekkan A, Ayoun Alsoud R, So S, Boulton DW.   +5 more
europepmc   +1 more source

Editorial: Biotechnology frontiers in pharmacology. [PDF]

Front Pharmacol
Vieira M, Santos C, Ferraz R.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Clinical Pharmacology of Cilazapril

Drugs, 1989
In clinical pharmacology studies, cilazapril, after its bioactivation to cilazaprilat, was characterised as a potent, reversible angiotensin converting enzyme (ACE) inhibitor with a terminal half-life of 30 to 50 hours, which is consistent with saturable binding to ACE.
C H, Kleinbloesem, P, Van Brummelen, R J, Francis, U W, Wiegand   +3 more
openaire   +3 more sources

Clinical Pharmacology of Inodilators

Journal of Cardiovascular Pharmacology, 1989
Recent advances in our knowledge of heart failure have shown that both a central and a peripheral factor are involved in this syndrome. Therefore, the ideal drug should combine the properties of a positive inotropic agent with those of a peripheral vasodilator; many drugs recently introduced into clinical practice have been shown to present both of ...
DEI CAS, Livio, METRA, Marco, VISIOLI, Odoardo   +2 more
openaire   +4 more sources

The chemistry, pharmacology and clinical pharmacology of diflunisal

Current Medical Research and Opinion, 1978
Studies are reviewed on diflunisal, a new analgesic agent with an improved therapeutic index, compared with acetylsalicylic acid, in animals and humans. Pharmacokinetic data indicate that a twice-daily dosage regimen of diflunisal is adequate for therapeutic purposes.
S L, Steelman, V J, Cirillo, K F, Tempero   +2 more
openaire   +2 more sources